Clinical SnapShots of Moderate-to-Severe Atopic Dermatitis
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
Atopic Dermatitis Overview and Pathogenesis
Atopic dermatitis endotypes and implications for targeted therapeutics.
Czarnowicki T, et al. J Allergy Clin Immunol. 2019;143(1):1-11.
Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Pathogenesis of atopic dermatitis.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Patient Burden and Comorbidities
Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march.
Holm JG, et al. Arch Dermatol Res. 2019;311(3):173-182.
The atopic march and atopic multimorbidity: many trajectories, many pathways.
Paller AS, et al. J Allergy Clin Immunol. 2019;143(1):46-55.
Association between atopic dermatitis and suicidality: a systematic review and meta-analysis
Sandhu JK, et al. JAMA Dermatol. 2019;155(2):178-187.
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults.
Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121(5):604-612
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Management of Atopic Dermatitis
Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy.
Ariëns LFM, et al. Ther Adv Chronic Dis. 2018;9(9):159-170.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape.
Boguniewicz M, et al. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
Strategies for successful management of severe atopic dermatitis.
Brar KK, et al. J Allergy Clin Immunol Pract. 2019;7(1):1-16.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, et al. J Am Acad Dermatol. 2020;82(2):377-388.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
New and emerging therapies for pediatric atopic dermatitis.
Nguyen HL, et al. Pediatric Drugs. 2019;21(4):239-260.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS, et al. J Am Acad Dermatol. Jun 2020. Epub Ahead of Print.
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.
Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.
Simpson EL, et al. JAMA Dermatol. 2020;156(1):44-56.
Guidelines
Guidelines of care for the management of atopic dermatitis: part 1. Diagnosis and assessment of atopic dermatitis.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.
Guidelines of care for the management of atopic dermatitis: part 2. Management and treatment of atopic dermatitis with topical therapies.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.
Guidelines of care for the management of atopic dermatitis: part 3. Management and treatment with phototherapy and systemic agents.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(2):327-349.
Guidelines of care for the management of atopic dermatitis: part 4. Prevention of disease flares and use of adjunctive therapies and approaches.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(6):1218-1233.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.
Patient Resources
International Eczema Council
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.
National Eczema Association
The National Eczema Association is a nonprofit organization founded in 1988 to improve the health and quality of life for individuals with eczema through research, support, and education.
Shared Decision Making Tool
Helping Your Patients and Their Families Understand Systemic Therapy For Moderate-To-Severe Atopic Dermatitis
Clinical Assessment Tools
Children’s Dermatology Life Quality Index (CDLQI)
CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children ages 4-16. (Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949).
Eczema Area and Severity Index (EASI)
EASI is a clinician assessment tool designed to measure clinical severity of atopic dermatitis. Severity scores can range from 0 (clear) to 72 (very severe). (Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18).
Investigator Global Assessment (IGA)
The IGA is a clinician assessment strategy designed to provide a snapshot of overall disease severity in dermatologic clinical trials. (Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294).
Patient-Oriented Eczema Measure (POEM)
The POEM is a patient-oriented, self-assessed measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting. (Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519).
Scoring Atopic Dermatitis (SCORAD)
SCORAD is a clinical tool used to assess the extent and severity of eczema. (Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.)
Clinically Relevant Pathophysiology of Atopic Dermatitis
Module 1
| Faculty: | Melinda Gooderham, MSc, MD, FRCPC; Diamant Thaҫi, MD |
| Release: | 10/30/2020 |
| Expiration: | 10/30/2021 |
Individualizing Patient Evaluations for Atopic Dermatitis
Module 2
| Faculty: | Melinda Gooderham, MSc, MD, FRCPC; Diamant Thaҫi, MD |
| Release: | 10/30/2020 |
| Expiration: | 10/30/2021 |
Multimodal Management for Patients with Moderate-to-Severe Atopic Dermatitis
Module 3
| Faculty: | Melinda Gooderham, MSc, MD, FRCPC; Diamant Thaҫi, MD |
| Release: | 10/30/2020 |
| Expiration: | 10/30/2021 |
Shared Clinical Decision Making in Atopic Dermatitis
Module 4
| Faculty: | Melinda Gooderham, MSc, MD, FRCPC; Diamant Thaҫi, MD |
| Release: | 10/30/2020 |
| Expiration: | 10/30/2021 |
